Predicting Inflammatory Bowel Disease Severity Through Genomic Risk

Approximately 60,000 people in Denmark live with chronic inflammatory bowel disease (IBD). While some experience mild symptoms, others face a debilitating course of illness often requiring surgery and a stoma¹. A significant challenge in managing IBD is the difficulty in predicting an individual’s disease progression at the time of diagnosis, leading to potential over- or under-treatment.

New Research Offers Hope for Personalized Treatment

A recent Danish study from the DNRF Center of Excellence PREDICT at Aalborg University suggests it may be possible to predict severe disease courses in newly diagnosed IBD patients. Researchers found a correlation between a higher genetic risk of developing IBD and a greater risk of experiencing a severe disease course².

Combining Data for a Comprehensive Approach

The study combined national registry data, clinical data and samples from Denmark’s National Biobank, encompassing nearly 8,300 Danes with chronic IBD. The results were published in the journal Gastroenterology².

The Role of Genetic Risk

Currently, there is no cure for chronic IBD. Management focuses on controlling symptoms with medication or, in some cases, surgically removing the affected intestinal section. However, many patients experience relapses requiring treatment adjustments, and disease courses vary significantly¹. Marie Vibeke Vestergaard, Research Assistant at Aalborg University, highlights the lack of a reliable clinical tool for tailoring treatment strategies¹. The new findings represent initial steps toward truly personalized treatment.

Building on Previous Findings

This correlation between genetics and disease severity builds upon previous research from the same group, which identified the gene HLA-DRB1*01:03 as significantly increasing the risk of major surgery in individuals with ulcerative colitis³.

Future Directions: Identifying Biological Markers

While these studies mark progress toward tailored treatment, further research is needed to identify the biological markers crucial for preventing and managing individual disease progression. Future studies will focus on determining the optimal medication and treatment strategies for specific subgroups of patients¹.

“We know that genetics is only one of many factors that play a role in the development of the disease and its severity,” adds Vestergaard. “we will also continue our research. Hopefully, the results will contribute to doctors being able to offer more precise treatments in the future, so that more patients benefit from a much milder disease course”¹.

Understanding Stomas in IBD

For some IBD patients, surgery involving a stoma – an opening in the abdomen diverting waste into a bag – may be necessary. Stomas can be temporary or permanent, depending on the extent of intestinal damage and the possibility of reconnection⁴. Different types of stomas exist, including colostomies (from the colon) and ileostomies (from the ileum)^{3, 4}. A multidisciplinary approach involving gastroenterologists, surgeons, and stoma nurses is essential for patients facing stoma creation³.

The Burden of Illness After Ostomy Creation

Research indicates a significant health and financial burden for individuals with an ostomy. Healthcare costs are substantially higher for those with an ostomy compared to matched controls, with costs remaining elevated even in the second year after creation⁵. Hospitalization and outpatient services are primary cost drivers, with ostomy-related complications contributing to 8-16% of hospitalization expenses⁵.

Key Takeaways

• Genetic risk is associated with the severity of inflammatory bowel disease.
• New research aims to personalize IBD treatment based on individual genetic profiles.
• Stoma surgery may be necessary for some IBD patients, but carries a significant health and financial burden.
• A multidisciplinary approach is crucial for managing IBD and providing optimal stoma care.